摘要
BRAF V600E和端粒酶逆转录酶(telomerase reverse transcriptase,TERT)启动子均在甲状腺肿瘤中存在一定比例的突变。在细针穿刺活检标本中检测BRAF V600E和TERT启动子突变有助于提高细胞学诊断准确率。BRAF V600E和TERT启动子突变可能与甲状腺肿瘤患者的临床病理特征和相对较差的临床预后有相关性,尤其是二者双突变的甲状腺癌患者表现出更高的侵袭性和不佳的临床预后。BRAF V600E突变常常会导致甲状腺癌患者的放射性碘治疗效果差或失败,而BRAF抑制剂有可能成为伴有BRAF V600E突变的甲状腺癌患者有效的靶向治疗药物。
Both BRAF V600E and TERT promoter mutations occur in thyroid tumors.Detection of BRAF V600E and TERT promoter mutations in fine-needle aspiration specimens helps to improve the accuracy of cytological diagnosis.BRAF V600E and TERT promoter mutations may have a relationship with clinicopathological features and poor clinical outcomes of patients with thyroid tumors,and thyroid tumor with double mutation may be related to higher invasiveness and worse clinical outcomes.BRAF V600E mutation often leads to poor or failed radioiodine therapy in patients with thyroid cancer,and BRAF inhibitors may be a hopeful targeted therapy for patients with BRAF V600E mutation.
作者
杨红(综述)
廖琼(审校)
Yang Hong;Liao Qiong(Department of Pathology,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,Sichuan,China)
出处
《肿瘤预防与治疗》
2020年第7期626-631,共6页
Journal of Cancer Control And Treatment
